Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Takeda joins Novartis and Merck in $45M funding for Koneksa Health
Fierce Biotech
Mon, 02/7/22 - 10:10 am
Tags:
Takeda Ventures, Novartis, Merck, Koneska Health, biomarkers, digital biomarkers, funding
No news anytime soon on Sandoz sale, says Novartis
Pharmaforum
Thu, 02/3/22 - 10:35 am
Tags:
Novartis, Vas Narasimhan, Sandoz, generics, M&A
Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing
NASDAQ
Wed, 02/2/22 - 11:44 pm
Tags:
Novartis, earnings, Sandoz
Novartis says Leqvio launch will feature a 'modest initial ramp,' but blockbuster potential awaits
Fierce Pharma
Wed, 02/2/22 - 11:10 am
Tags:
Novartis, Leqvio, drug launches, Cardiovascular
Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data
Fierce Biotech
Wed, 02/2/22 - 10:59 am
Tags:
Novartis, Incyte, JAK inhibitors, Opzelua, eczema, atopic dermatitis
Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig
Fierce Pharma
Tue, 02/1/22 - 11:28 pm
Tags:
Amgen, Novartis, Aimovig, migraines, SEC
Novartis' Sandoz reportedly the target of $25B buyout bid from Carlyle and Blackstone
Fierce Pharma
Tue, 02/1/22 - 11:26 pm
Tags:
Novartis, Sandoz, M&A, Blackstone, Carlyle
Biotech investors pray for a takeover miracle
EP Vantage
Fri, 01/14/22 - 11:09 am
Tags:
M&A, biotech, Amylyx Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Aurinia Pharmaceuticals, Biogen, Biohaven, Bristol Myers Squibb, Eli Lilly, GSK, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says
Fierce Pharma
Thu, 01/13/22 - 11:06 am
Tags:
JPMHC 2022, Novartis, Leqvio, drug launches, Regeneron, Amgen, Sanofi
Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?
Endpoints
Mon, 01/10/22 - 11:31 pm
Tags:
Novartis, Molecular Partners, clinical trials, COVID-19, antivirals, ensovibep
#JPM22, Day 1: Bristol Myers Squibb's blockbuster losses of exclusivity, Novartis' spending plans and more
Fierce Pharma
Mon, 01/10/22 - 11:38 am
Tags:
JPMHC 2022, Bristol Myers Squibb, Revlimid, Novartis, Moderna Therapeutics, JNJ, Trikafta
Novartis turns to Alnylam in research deal aimed at liver failure
BioPharma Dive
Thu, 01/6/22 - 10:57 am
Tags:
Novartis, Alnylam Pharmaceuticals, liver failure
Teva and Novartis’ Sandoz launch Narcan generics on same day, brand marketer Emergent remains in play
Endpoints
Wed, 01/5/22 - 10:47 pm
Tags:
Teva Pharmaceutical, Novartis, Sandoz, generics, Narcan, Emergent BioSolutions
Novartis blocks generic to MS blockbuster Gilenya in US patent dispute
Pharmaforum
Tue, 01/4/22 - 10:50 am
Tags:
Novartis, Gilenya, patents, HEC Pharma, generics, multiple sclerosis, MS
It Was To Be The Cholesterol Drug For The Masses. Novartis Changed That.
Forbes
Mon, 01/3/22 - 10:42 am
Tags:
Novartis, inclisiran, Leqvio, cholesterol
FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents
Pharmaceutical Business Review
Sun, 12/26/21 - 11:17 pm
Tags:
Novartis, FDA, Cosentyx, arthritis, pediatric
2022 forecast: Will biopharma's offices ever go back to 'normal'? Sanofi, Novartis and more chime in
Fierce Pharma
Wed, 12/22/21 - 11:37 pm
Tags:
COVID-19, pandemic, remote work, Sanofi, Biogen, Pfizer, Novartis
Novartis wins FDA approval for new heart drug, but faces uphill sales battle
BioPharma Dive
Wed, 12/22/21 - 11:35 pm
Tags:
Novartis, FDA, Leqvio, cholesterol
Novartis to acquire Gyroscope Therapeutics, gaining ocular gene therapy
Biopharma Reporter
Wed, 12/22/21 - 11:16 am
Tags:
Novartis, Gyroscope Therapeutics, ocular gene therapy, gene therapy, M&A
Blow for Novartis as ligelizumab can’t top Xolair in phase 3
Pharmaforum
Mon, 12/20/21 - 11:01 am
Tags:
Novartis, ligelizumab, clinical trials, chronic spontaneous urticaria, Xolair

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.